Molina Healthcare (NYSE:MOH) experienced a sharp decline in after-hours trading Wednesday, with shares falling 9.4% to $200.85, despite reporting an earnings beat and raising its full-year guidance. The preliminary quote at 18:09 EDT reflected investor skepticism about the sustainability of the company's margins, as a key metric revealed that the first half of 2026 already accounted for the majority of the company's adjusted earnings floor.
The company reported adjusted earnings per share (EPS) of $3.86 for the first half of 2026, which represents 73.5% of its newly established $5.25 floor for the full year. This leaves a remaining gap of $1.39 to be achieved in the second half, equivalent to 26.5% of the floor. While the company can still finish above guidance, the market's reaction suggests that investors are focused on the trajectory of margins rather than the headline numbers.
For the second quarter, Molina reported adjusted EPS of $1.51, surpassing the pre-report consensus estimate of $1.39 by 8.6%. Total revenue of $10.874 billion also exceeded expectations by 0.4%, coming in above the $10.83 billion estimate. However, the medical care ratio (MCR) rose to 92.2%, up 180 basis points from 90.4% a year earlier, signaling cost pressures that weighed on profitability.
On a year-over-year basis, the figures were notably weaker. Premium revenue declined 6% as membership fell, while adjusted EPS dropped sharply from $5.48 to $1.51. The company attributed the 25-cent increase in guidance to first-half Medicaid results, but noted that improvements in the Medicare outlook by $1.50 per share were offset by a $1.50 decline in the Marketplace segment, resulting in no net change to the overall guidance.
CEO Joseph Zubretsky commented that the imbalance between Medicaid rates and medical cost trend appears to have stabilized, and he expects future rate increases to correct the gap. The company continues to characterize 2026 as the trough for Medicaid pretax margins, but investors appear to require more concrete evidence of a turnaround.
Cost pressures were evident across the board, with the consolidated MCR rising to 92.2% from 90.4%. The Marketplace segment's MCR reached 88.9%, above Molina's expectations, driven by unfavorable acuity and risk-adjustment effects. These headwinds contrast sharply with peers: UnitedHealth Group (NYSE:UNH) reported a 270-basis-point reduction in its MCR to 86.7% last week, and its shares gained nearly 8%. Elevance Health (NYSE:ELV) saw its benefit expense ratio rise 80 basis points to 89.7%, though business mixes differ.
U.S. cash markets were closed at the dateline. Molina ended Wednesday down 2.1% at $221.74, which was 1.4% below its July 16 close and 9.5% under its July 14 high. The stock joined the S&P MidCap 400 before Wednesday's open, and Tuesday's volume reached 9.7 million shares, nearly ten times its 50-day average.
Looking ahead, Molina's earnings call is scheduled for Thursday at 8:00 a.m. EDT, where management will face questions on Marketplace acuity, state rate timing, and Florida start-up costs. Centene Corporation (NYSE:CNC) reports on July 28, offering the next Medicaid-heavy peer comparison. Risks remain two-sided: faster rate updates or softer utilization could lift earnings above the floor, while worse Marketplace acuity, delayed rates, or Florida losses above guidance could reduce it. For now, Molina has booked most of its stated floor, but the stock reaction shows investors want proof that margins are turning.
